We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bodisen | BODI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.00 | 6.00 |
| Top Posts |
|---|
Posted at 16/5/2014 20:47 by skier100 Question for BODI long-termers -- what, in your view, drove the spike in trading volumes and share price today?Thanks in advance. |
Posted at 15/2/2011 08:01 by mattjos keya .. book value in the usa is $2.50 ... i don't expect that sort of price for a while yet but, this stock has historically been heavily shorted in the usa. if the shorts have to start closing, who knows where it will go.am really waiting for news from CPDU which will influence how quickly BODI can realise the value of its stake there + progress on the new plant in Xinjiang. meantime, it simply looks too cheap - so, I've been a buyer |
Posted at 01/8/2007 13:00 by cimbom RNS Number:3160BBodisen Biotech Inc 01 August 2007 1 August 2007 Bodisen Biotech, Inc. ("Bodisen" or the "Company") Contract Win Bodisen Biotech, Inc. (the "Company") (London AIM: BODI; OTC Pink Sheets: BBCZ; website: www.bodisen.com) today announces its first export contract win. The Company announces it has signed a contract with RADUGA Co., Ltd. through Aoshen Imports and Exports Co., Ltd in the city of Huhehaote in the Inner Mongolia Autonomous area for export to customers in Russia. This contract is for approximately 2.3 million RMB in products and represents the first international export order for the Company. Management Appointment The Company also announces that Ms Junyan Tong, age 36, has been appointed to serve as the Company's Chief Financial Officer Ms Tong has previously served as the Company's Assistant Chief Financial Officer since 2005. This is not a main board appointment. From 1998 -2002, Ms Tong was Chief Financial Officer of Shenzhen Rongxun Industry Co., Ltd., and between 1995- 1998, Ms Tong served as Financial Manager of Guangdong Zhongyunhui Electric Co., Ltd. About Bodisen Biotech, Inc. Bodisen Biotech, Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. The Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly "green" products have been proven to improve soil and plant quality and increase crop yields. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties, and the outcome of events may differ materially from those described in the forward-looking statements. Enquiries: Bodisen Investor Relations Scott King - 001 219 939 3073 info@bodisen.com Charles Stanley Securities (Nominated Adviser) Rick Thompson / Philip Davies / Carl Holmes - 0207 149 6000 This information is provided by RNS The company news service from the London Stock Exchange END NRAUAOARBRRWRAR |
Posted at 24/7/2007 11:34 by miamisteve My reinvestment of the cash I pulled out of BODI has now made back 100% of my losses although because bodisen are a significant shareholders in CHNG I think Wong will have one more laugh at my expense with some pressure on the CHNG share price due to these results. |
Posted at 01/5/2007 13:47 by leighbarton Any comment on the results is outweighed by the Amex delisting and resultant litigation proceedings. A number of points from the filing:Wey got massive compensation, previously undisclosed from the various placings. $5m from the AIM listing alone. Why? Part of the proceeds for the placing were to be used to build a factory in the NE. They subsequently decided not to do this. Why? what has the money been used for instead? The company is making loans left right and centre. Huge advances to its suppliers, even larger ones to its customers. This now has risen to $18m. Remember this is to pure peasant farmers. No issue when things are going well, but should there be a drought then these farmers will have no reserves to honour their commitments. At $7m I was fairly relaxed about this, but this has soared since the interims. It would be good to have a geographic analysis of where these loans are distributed to see the exposure the company has to drought prone regions. Corporate Governance is clearly an issue here with previously undisclosed dealings by the management and founding investors, distributions of which were made from a reserve over the last financial period. 738,000 shares are still o/s in this regard (shares unclaimed by fouding investors). What's this all about. All these factors I think cloud what otherwise look a healthy set of numbers. The risk factor I think is just too high, with the possibility that the company could still take a hammering. Not tempted back in in spite of (maybe because of) the recovery in share price. A real shame but it does highlight the potential risks of investing in Chinese entities. Let's hope BODI is a one off, and got away with it because it did reverse into the market as opposed to going through the rigours of an IPO. |
Posted at 20/3/2007 10:27 by pictureframe only a fool would buy this, looks like a scam imhoIn September 2005, Qiong Wang and Bo Chen made stock transfers to individuals identified as their children. The Company also understands that the children made substantial stock transfers shortly thereafter to persons residing in the People's Republic of China on whose behalf the shares were held by Ms. Wang, Mr. Chen and the children. The Company understands that some or all of the 19 stockholders of Bodisen International, Inc. (which, prior to the "reverse merger", was the parent of what now is the Company's principal operating subsidiary) who received stock in the "reverse merger" held at least a portion of such shares on behalf of additional persons residing in China, with respect to which transfers have not yet been made. The exact nature and extent of these interests are not yet known, including whether they support claims against individual stockholders or, in contrast, claims against the Company. As a result, at this time, the Company cannot eliminate the possibility that, to the extent such interests exist and support claims against the Company, they would constitute a material liability or materially impact the capitalization of the Company. As a result of the reverse merger and after giving effect to the 3-for-1 stock dividend paid in 2004, these 19 stockholders originally held of record 12,000,000 shares of the Company's common stock, of which Ms. Wang was the record holder of 3,748,780 shares and Mr. Chen was the record holder of 3,584,096 shares. According to the records of the Company's transfer agent, Qiong Wang currently is record holder of 720,000 shares of the Company's common stock and Bo Chen currently is record holder of 690,000 shares of the Company's common stock. According to the records of the Company's transfer agent, the children of Qiong Wang and Bo Chen currently together hold 2,639 shares |
Posted at 16/11/2006 17:45 by zho 16.11.2006 - RC Group makes its markEveryone has been knocking the UK's relatively lightly regulated AIM market recently but part of this is due to its runaway success in attracting exciting young companies from all over the World. There have been so many new issues over the last 12 months that many are now referring to " AIM Fatigue " with brokers' clients simply unable to absorb any new offerings. The other reason why investors are a little more circumspect is the fact that so many foreign companies do not quite have the same grasp of corporate governance as their UK counterparts. Just in the last few days, BODISEN BIOTECH, the Chinese fertiliser manufacturer, which we have tipped several times, has been instructed by the American Stock Exchange to sever links with a somewhat dubious corporate finance consultancy in Oklahoma. This has sent the shareprice into a tailspin despite quarterly figures announced the next day showing that profits for the first 9 months are ahead by another breathtaking 75 %. BODI should earn around 40p for the full year leaving the shares at 300p selling at a mere 7.5 times earnings. This is silly money for a company growing at such a rapid rate and the shares should bounce back strongly if, as we suspect, the company's minor misdemeanour is proved to be more down to naivity than anything more sinister. The Bodisen experience underlines what a double - edged sword the AIM market can be at times. AIM investors are spoilt for choice with so many of the World's fastest growing companies to choose from ( Bodisen for instance is ranked by Forbes as the 16th fastest growing company in China )but the downside is that things do not operate on the far side of the globe quite the same as they do in London . Those who are prepared to take the rough with the smooth and accept the added risk involved have a number of real AIM bargains from which to choose. Take, for example, the HongKong based RC Group who manufacture biometric security devices involving fingerprint and facial recognition systems. Because of the way the World is nowadays, this market is forecast to grow from $ 2.1 billion this year to $ 5.7 billion in 2010 and RCG is on course to grab a healthy slice of this cake via vigorous organic growth and an equally brisk acquisition programme. The latest interim figures speak for themselves with organic revenues up by over 200% and acquired revenues adding a further sizeable chunk leaving a grand total of 371%. Pretax profit growth was just as impressive - up 357%. Brokers, Corporate Synergy, are forecasting earnings per share of about 7 p for the full year suggesting that the shares, which have already doubled this year to 71p, are still only selling on a price earnings multiple of 10. There should also be a small but fast growing dividend payout to anticipate. If RCG was headquartered in the UK, you would probably expect to pay nearer 20 times earnings for this one - you pays your money and takes your choice ! You can read all about RC Group's leading edge technology and products at www.rcg.tv. |
Posted at 03/10/2006 14:16 by cimbom This article is one of the few articles which tell the story as it is with an unbiased view.Bodisen Biotech Inc.: Chinese Fertilizer Company's honeymoon on AIM, NYSE hits a bump By William Foss The 28th of March was a big day for Bodisen Biotech. The company's maiden results since initiating a primary listing in New York and a secondary listing in London were closely watched by many pundits on both sides of the Atlantic to see how the fertiliser company faired. Compared to 2004, revenues grew 91% to USD $31 million and net income was up 75% to USD $8.8 million. Furthermore, the order book for 2006 is already greater than 2005 and the company has also received an additional 2 year leave from paying Income Tax. Not to mention that during 2005, Bodisen successfully doubled it's organic fertiliser capacity and also acquired a strategic stake in China Natural Gas Company (OTCBB: CHNG). Since moving onto the New York & London boards, Bodisen's market capitalisation has reflected an expectation of strong growth going forward, and the company didn't disappoint. Bodisen currently has over 60 products on offer to farmers in over 20 provinces in China. The company boasts that its organic fertilizers are competitvely priced to chemical alternatives, but also offer up to 35% higher crop yields, improved soil conditions and also allows farmers to increase their own selling price by having their produce certified as organic green foods. Bodisen intends to aggressively expand market reach in China, and has also used the increased awareness from the dual listings as a way to start negotiations to form joint ventures with companies in the west. Perhaps the most compelling statistic of all supplied by Bodisen, is the fact that of the 1.3 billion people living in China, 900 million are farmers whose livelihood is dependent on crop yields - a massive market. Bodisen currently generates 67% of it's revenues from organic fertilisers - over the next 5 years organic fertilisers are expected to increase in use from 6% to 20% of the overall USD $25 billion Chinese fertiliser market. So why have the shares plunged this morning? Until this weekend the company had enjoyed a positive start to its life on the AMEX and LSE. Forbes Magazine named it as one of the Top 20 fastest growing companies in China, and the recent secondary London listing was claimed to be three times oversubscribed (Bodisen raised £12 million). The cash is earmarked for the construction of two new manufacturing plants, one in Helongjiang and the other in Xinjiang and also for purchasing raw materials and working capital. In January this year China also added a boost to Bodisen's business by eliminating a 15.5% agricultural tax on farm output as part of wider reforms to encourage greater productivity and output from China's agricultural industry to meet growing needs of the domestic economy. However, this weekend the NY Post raised concerns over Bodisen's business, the lack of analyst coverage, and the apparent lack of transparency of the company's auditors and US broker. What the NY Post forgot to mention was that London based Charles Stanley Securities have written a note on the company too, but this is only available to institutional investors in the UK. Perhaps Bodisen should consider having an independant research note written to quell the critics? Bodisen originally reversed into an OTCBB company a few years ago and then moved onto the American Stock Exchange main list last year. The secondary listing in London was an attempt to broaden the companies shareholder base and bring in some institutional support - a look at the volumes traded in New York compared to London quickly reveals that this stock is held by a large number of retail investors in the United States. Bodisen appears as a very simple business selling an ordinary product into an extraordinary market. However, we spoke to some investors who have visited Bodisen's operations in China, and the impression was that the company is anything but simplistic: Bosidens operations actually incorporates a high level of sophistication, modern factories, and the company also has a sound understanding of the importance of marketing and brand awareness. Going forward Bodisen has net cash in excess of USD $20 million, a rapidly expanding market to sell its products into and the potential to aggressively grow at home and abroad. On the flip side the company is trading on an high earnings ratio, so any slip ups could be severly punished, as was shown today when a little negative press comment created a severe drop. |
Posted at 01/9/2006 13:01 by cimbom Bodisen Biotech to Present at the Roth Capital Partners 2006 New York Conference on September 6th8/30/2006 NEW YORK, NY, Aug 30, 2006 (MARKET WIRE via COMTEX News Network) -- Bodisen Biotech, Inc. (AMEX: BBC) (AIM: BODI) (website: www.bodisen.com), the first China-based environmentally friendly bio fertilizer company listed on a U.S. stock exchange, and dually listed in London, today announced that it will present at the Roth Capital Partners 2006 New York Conference on September 6th at 1:30 pm at the Westin Times Square Hotel in New York City. Chairman and Chief Executive Officer, Karen Qiong Wang, and President Bo Chen will be present at the conference. Bodisen's management will update investors regarding the company's growth strategies, including its recently announced expansion into China's vast Xinjiang province. Bodisen reported fully diluted Earnings Per Share of $0.32 for the 2nd quarter ended June 30, 2006. The Company also cited positive growth outlook for the second half of 2006 and 2007 given strong product demand and Bodisen's strategic expansion into new markets. A live webcast of the audio presentation will be available along with accompanying presentation slides. Interested parties may tune in to the live presentation by visiting: About Bodisen Biotech, Inc. A Delaware company, Bodisen is headquartered in Shaanxi, China's agricultural hub. In January 2006, Bodisen was ranked the 16th fastest growing company in China by Forbes China. The Bodisen brand is a highly recognized fertilizer brand in China. Its environmentally friendly "green" products support the mandate of the Chinese government to increase crop yields for the purpose of decreasing China's dependency on food imports. Utilizing proprietary agricultural technologies, Bodisen sells over 60 packaged products, broken down into 4 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; Pesticides & Insecticides; and agricultural raw materials. Bodisen's organic fertilizers are government certified as "organic" and can be absorbed by plants within 48 hours and enrich soil conditions without the damaging effects associated with chemical fertilizers. Bodisen's products address grains, vegetables, and fruit crops and have been proven to increase crop yields by 10% to 35% while being environmentally friendly. Among China's population of 1.3 billion, approximately 750 million are farmers or have agriculture related jobs whose incomes depend on their crop yields. With approximately 600 (and growing) nationwide distribution centers, Bodisen has experienced rapid growth. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Contact: Investor Relations: Debra Chen The Piacente Group, Inc. 212-481-1907 SOURCE: Bodisen Biotech, Inc. Copyright 2006 Market Wire, All rights reserved. |
Posted at 15/8/2006 14:12 by cimbom Bodisen Biotech to Present at the Roth Capital Partners 2006 New York Conference in Early SeptemberNEW YORK, NY -- (MARKET WIRE) -- August 15, 2006 -- Bodisen Biotech, Inc. (AMEX: BBC) (AIM: BODI) (website: www.bodisen.com), the first China-based environmentally friendly bio fertilizer company listed on a U.S. stock exchange, and dually listed in London, today announced that it will present at the Roth Capital Partners 2006 New York Conference. The conference is being held September 6-7, 2006 at the Westin Times Square Hotel in New York City. Chairman and Chief Executive Officer, Karen Qiong Wang, and President Bo Chen will present at 1:30 p.m. Eastern Time on Wednesday, September 6, 2006. Karen Qiong Wang, Chairman & CEO of Bodisen, commented, "We look forward to having this opportunity to share Bodisen's bright outlook with investors and also highlight the tremendous earnings growth that the Company has been able to deliver quarter after quarter over the past two and a half years since becoming a public company. We expect our recent expansion into China's vast Xinjiang province to contribute significantly to our 2007 earnings and beyond. Bodisen's management team is focused on executing another excellent quarter for the third quarter especially given that we are already in the middle of our third quarter, which historically has been our strongest quarter of the year." On August 14, 2006, Bodisen reported record revenues of $16.4 million for the second quarter of 2006, up 95% from the prior year period and net income of $5.9 million (or fully diluted EPS of $0.32), up 118% from the prior year period. The Company also cited positive growth outlook for the second half of 2006 and 2007 given strong product demand and Bodisen's strategic expansion into new markets. A live webcast of the audio presentation will be available along with accompanying presentation slides. Interested parties may tune in to the live presentation by visiting: About Bodisen Biotech, Inc. A Delaware company, Bodisen is headquartered in Shaanxi, China's agricultural hub. In January 2006, Bodisen was ranked the 16th fastest growing company in China by Forbes China. The Bodisen brand is a highly recognized fertilizer brand in China. Its environmentally friendly "green" products support the mandate of the Chinese government to increase crop yields for the purpose of decreasing China's dependency on food imports. Utilizing proprietary agricultural technologies, Bodisen sells over 60 packaged products, broken down into 4 product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; Pesticides & Insecticides; and agricultural raw materials. Bodisen's organic fertilizers are government certified as "organic" and can be absorbed by plants within 48 hours and enrich soil conditions without the damaging effects associated with chemical fertilizers. Bodisen's products address grains, vegetables, and fruit crops and have been proven to increase crop yields by 10% to 35% while being environmentally friendly. Among China's population of 1.3 billion, approximately 750 million are farmers or have agriculture related jobs whose incomes depend on their crop yields. With approximately 600 (and growing) nationwide distribution centers, Bodisen has experienced rapid growth. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. -------------------- Investor Relations: Debra Chen The Piacente Group, Inc. 212-481-1907 SOURCE: Bodisen Biotech, Inc. -------------------- Back To Recent News Issuers of news releases, not Market Wire, are solely responsible for the accuracy of the content. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
